Actively Recruiting
Randomized, Double-Blind Study of Daily Oral LUM-201 Versus Placebo in Children Aged 3 to 11 With Growth Hormone Deficiency A Multicenter 12-Month Phase 3 Trial Evaluating Safety and Effectiveness
Led by Lumos Pharma · Updated on 2026-10-19
150
Participants Needed
55
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating LUM-201 as a treatment for Pediatric Growth Hormone Deficiency PGHD in children who have not previously received treatment. This multinational Phase 3 clinical trial aims to assess the safety and effectiveness of daily oral LUM-201 and to validate a predictive marker to identify children most likely to respond to this therapy. The study compares daily oral doses of LUM-201 at 1.6 mgkg to a matched placebo, in a randomized, double-blind manner. Participants are prepubertal children aged 3 to 11 years, treated over a 12-month period. The trial measures growth outcomes while monitoring safety and response to the medication. Participants undergo regular assessments including growth measurements and hormone evaluations over the year-long treatment. The primary outcome is annualized height velocity after 12 months of treatment with LUM-201 compared to placebo. Safety is monitored throughout the trial, with follow-up continuing until study completion in early 2028.
CONDITIONS
Brief Title
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
Research Team
L
Lumos Pharma
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here